장덕_서브상단배너

Home > 치료사례 > 연구논문

연구논문

이미지명

Effect and Mechanism of Ginsenoside Rg3 on Postoperative Life Span of Patients with Non-Smali Cell L

Chinese Journal of Integrative Medicine

Chin J Integr Med 2008 Mar:14(1):33-36

 

Effect and Mechanism of Ginsenoside Rg3 on Postoperative Life Span of Patients with Non-Smali Cell Lung Cancer

 

LUPing, SU Wei, MIAO Zhan-hui, NIU Hong-rui, LIU Jing, and HUA Qin-liang

 

ABSTRACT

Objective: To explore the effect and mechanism of ginsenoside Rg3 on the postoperative life span of patients with non-small cell lung cancer (NSCLC).
Methods: The prospective, randomized, controlled method was adopted. One hundred and thirtythree patients with NSCLC were randomly assigned to 3 groups: Shenyi Capsule group (43 cases), combined therapy group (Shenyi Capsule plus chemotherapy, 46 cases), and chemotherapy group (44 cases), the survival rates, immune function and the correlation between vascular endothelial
growth factor (VEGF) expression and clinical effect were analyzed in the three groups.

Results:

(1) The 1-year survival rate in the Shenyi group, the combined group and the chemotherapy group was 76.7% (33/43), 82.6% (38/46), and 79.5% (35/44), respectively; the 2-year survival rate was 67.4% (29/43), 71.7% (33/46), and 70.5% (31/44), respectively; and the 3-year survival rate was 46.5% (20/43), 54.3% (25/46), and 47.7% (21/44), respectively. There was no significant difference among the 3 groups (P>0.05).

(2) NK cells were increased to different degrees and the ratio of CD4/CD8 was normal in the Shenyi Capsule group and the combined group, while the ratio of CD4/CD8 was disproportional in the chemotherapy group.

(3) In the chemotherapy group, the 3-year survival rate was lower in patients with positive expression of VEGF than in patients with negative expression (37.0% vs 64.7%, x^=17.9, P<0.01), but no significant statistical difference was shown in the other two groups (53.6% vs 55.6%, P>0.05; 44.4% vs 50.0%, P>0.05). Conclusion: Shenyi Capsule, especially in combination with chemotherapy, can improve the life span of patients with NSCLC after operation. The mechanism might be correlated with improving the immune function and anti-tumor angiogenesis.


KEY WORDS non-small cell lung cancer, Shenyi Capsule, vascular endothelial growth factor, life span

 

 

게시글 공유 URL복사
댓글[0]

열기 닫기